5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction

To assess the effects of 5-alpha-reductase inhibitors (5ARIs) for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic obstruction (BPO).

This is a protocol.